Publications

• Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
  Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., & Khavari, P. A. (2015). Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nature genetics, 47(9), 1056-1060.
• Targeting CD137 enhances the efficacy of cetuximab.
  Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., & Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. journal of clinical investigation, 124(6), 2668-2682.
• Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.
• Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., & Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97-S101.
  
• Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma Weng, W. K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214).
  
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.
  
• The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., & Rook, A. H. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. AMERICAN JOURNAL OF HEMATOLOGY, 87(4), 354-360.
  
• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.
  
• Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., & Levy, R. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. JOURNAL OF CLINICAL INVESTIGATION, 122(3), 1066-1075.
  
• Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., & Khavari, P. A. (2012). Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts. BLOOD, 120.
  
• Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.
  
• Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.
  
• The IgG Fc Receptor FcγRIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma Weng, W. K., Negrin, R., Lavori, P., & Horning, S. J. (2010). The IgG Fc Receptor FcγRIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28.
  
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
  
• Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W.-K., Ingolia, D., & Levy, R. (2009). Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 50(1), 37-46.
  
• Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma Weng, W. K., & Levy, R. (2009). Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma. LEUKEMIA & LYMPHOMA, 50(9).
  
• Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab Weng, W. K., & Levy, R. (2009). Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. LEUKEMIA & LYMPHOMA, 50(5:723-727).
  
• A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma Racila, E., Link, B. K., Weng, W.-K., Witzig, T. E., Ansell, S., & Weiner, G. J. (2008). A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. CLINICAL CANCER RESEARCH, 14(20), 6697-6703.
  
• The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., & Younes, A. (2008). The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. BLOOD, 112(3), 711-720.
  
• Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy. Weng, W. K., Czerwinski, D., & Levy, R. (2007). Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy. BLOOD, 109.
  
• Immune-mediated antitumor effects with antibody therapy. Weng WK. (2005). Immune-mediated antitumor effects with antibody therapy. American Society of Clinical Oncology Educational Book.
  
• Immunoglobulin G Fc polymorphism is correlated with rituximab-induced neutropenia following autologous hematopoietic cell transplantation. Weng, W. K., Horning, S. J., Negrin, R. S., & Levy, R. (2004). Immunoglobulin G Fc polymorphism is correlated with rituximab-induced neutropenia following autologous hematopoietic cell transplantation. BLOOD, 104(11), 129A-129A.
  
• Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., & Levy, R. (2004). Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. JOUNRAL OF CLINICAL ONCOLOGY, 22.
  
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma Weng, W. K., & Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 21(21), 3940-3947.
  
• Hepatitis C virus (HCV) and lymphomagenesis Weng, W. K., & Levy, S. (2003). Hepatitis C virus (HCV) and lymphomagenesis. LEUKEMIA & LYMPHOMA, 44(7), 1113-1120.
  
• Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Weng, W. K., & Levy, R. (2001). Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. BLOOD, 98(5), 1352-1357.
  
• Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells Weng, W. K., Shah, N., O'Brien, D., Van Ness, B., & LeBien, T. W. (1997). Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells. JOURNAL OF IMMUNOLOGY, 159(11), 5502-5508.
  
• SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS Weng, W. K., Jarvis, L., & LeBien, T. W. (1994). SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(51), 32514-32521.
  
• FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS Wolf, M. L., Weng, W. K., STIEGLBAUER, K. T., Shah, N., & LeBien, T. W. (1993). FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS. JOURNAL OF IMMUNOLOGY, 151(1), 138-148.